期刊文献+

HPLC-MS/MS法测定人体血清中替加色罗的浓度

HPLC-MS/MS determination of tegaserod concentration in human serum
下载PDF
导出
摘要 目的:建立一种测定人体血浆中替加色罗血药浓度的液相色谱-质谱/质谱的方法。方法:色谱柱:Liehrospher C_(18)(150mm×4.6 mm,5μm),流动相:甲醇-水(含2.5 mmol·L^(-1)醋酸铵,1%甲酸)(75:25),流速:0.5 mL·min^(-1),柱温:25℃。内标为苯海拉明。质谱条件为电喷雾电离源(ESI),选择正离子检测,营加色罗:[M+H]^+离子 m/z 302.2,碎片子离子 m/z173.1,碰撞能量28 V;内标:苯海拉明[M+H]^-离子 m/z 256.2,碎片子离子 m/z 165.1,碰撞能量36 V。结果:本法线性范围:0.0361~7·215 ng·mL^(-1),r=0.9991(n=5),最低定量浓度为0.0361 ng·mL^(-1);方法的准确度在90%~115%之间;提取回收率(绝对回收率)>70%。批内、批间 RSD<10%。结论:本方法专属性强,灵敏度高,线性关系良好,适用于人体血浆中替加色罗的测定及药代动力学研究。 Objective : To establish an HPLC - MS/MS method for the determination of tegaserod in human serum. Method:The HPLC -MS/MS method was performed on a colume of Lichrospher C18 (150 mm ×4. 6 mm,5 μm). The mobile phase consisted of methanol - water( contained 2.5 mmol·L^-1 CH3 COONH4 and 1% HCOOH) (75: 25) at a flow rate of 0.5 mL ·min^-1. The temperature of column was 25 ℃. The internal standard was diphen- hydramine. ESI was applied and operated in positive mode. The parent ion of tegaserod and diphenhydramine [ M + H ]^+ m/z were 302.2 and 256.2, respectively,while the product ion for tegaserod and diphenhydramine were 173.1 and 165.1 ,respectively. Results:The linear range was 0. 0361 -7. 215 ng·mL^-1 ,r =0. 9991 (n =5). The limit of quantification was 0. 0361 ng·mL^-1. The method recovery was 90% - 115%, extracted recovery( absolute recovery ) was more than 70% ; The intra - day precision (RSD) and inter - day precision (RSD) were less than 10%. Conclusion:The method is specific, sensitive, and accurate, and suitable for the determination of tegaserod concentration in human serum and pharmacokinetic studies.
出处 《药物分析杂志》 CAS CSCD 北大核心 2008年第6期853-856,共4页 Chinese Journal of Pharmaceutical Analysis
关键词 HPLC—MS/MS 替加色罗 血药浓度 HPLC - MS/MS tegaserod human serum concentration
  • 相关文献

参考文献3

  • 1司继刚,郭瑞臣,王本杰.马来酸替加色罗胶囊与其片剂的人体生物等效性[J].中国临床药学杂志,2006,15(2):96-99. 被引量:6
  • 2Appel - Dingemanse S, Hirschberg Y, Osborne S, et al. Multiple - dose phalmacokineties confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919). Eur J Clin Pharmacol, 2001,56 : 889
  • 3Appel - Dingemanse S, ttorowitz A, Campestrini J, et al. The pharmanokinetics of the novel promotile drag, tegaserod, are similar in healthy subjects - male and female, elderly and young. Aliment Pharmacol Ther,2001, 15:937

二级参考文献5

  • 1Appel S,Kumle A,Hubert M,et al.First pharmacokinetic-pharmacodynamic study in humans with a selective-hydroxytryptamine 4 receptor agonist[J].J Clin Pharmacol,1997,37(3):229
  • 2Vickers AE,Zollinger M,Dannecker R,et al.In vitro metabolism of tegaserod in human liver and intestine:asseement of drug interactions[J].Drug Metab Dispos,2001,29(10):1269.
  • 3Apple-Dingemanse S,Hirschberg Y,Osborne S,et al.Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF919)[J].Eur J Clin Pharmacol,2001,56(12):889.
  • 4Appel-Dingemanse S,Horowitz A,Compestrini J,et al.The pharmacokinetics of the novel promotile drug,tegaserod,are similar in healthy subjects-male and female,elderly and young[J].Aliment Pharmacol Ther,2001,15(7):937.
  • 5沙云菲,高敏洁,段更利,刘浩,许盈,王以俭.高效液相色谱法及紫外分光光度法测定替加色罗片的含量[J].中国新药与临床杂志,2003,22(11):659-662. 被引量:6

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部